The American Recovery and Reinvestment Act of 2009 provided $1.1 billion for comparative effectiveness research (CER). The Patient Protection and Affordable Care Act established the Patient-Centered ...
Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...
The Center of Comparative Medicine and Pathology (CCMP) supports animal model use in cancer research through teams including the Research Animal Resource Center (RARC) and the Laboratory of ...
The Comparative Medicine shared resource provides a variety of research support services. All our facilities are fully accredited by the AAALAC International and comply with all U.S. Department of ...
In the article that accompanies this editorial, Lu et al 5 conducted a systematic review on the use of instrumental variable (IV) methods in oncology comparative effectiveness research. The main ...
Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging ...
PCORI also is offering up to $200 million through the Phased Large Awards for Comparative Clinical Effectiveness Research (PLACER) PFA, for ambitious, large-scale two-phased trials addressing critical ...
RARC is composed of the following sections: Aquatic Services and Systems, Biosecurity, Education and Quality Assurance, Husbandry and Operations, and Veterinary Services. RARC provides housing, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results